Outlook Therapeutics earnings were -$94.0M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest OTLK earnings report on Jun 30, 2024 announced Q2 2024 earnings of $44.4M, down 138.9% from last quarter. For the last reported fiscal year 2023 ending Sep 30, 2023, OTLK reported annual earnings of -$59.0M, with -10.7% growth. The next OTLK earnings date is Dec 20, 2024.
Outlook Therapeutics Earnings Reports & History FAQ
What were Outlook Therapeutics's earnings last quarter?
On OTLK's earnings call on Invalid Date, Outlook Therapeutics (NASDAQ: OTLK) reported Q2 2024 earnings per share (EPS) of $1.91, up 218.63% year over year. Total OTLK earnings for the quarter were $44.41 million. In the same quarter last year, Outlook Therapeutics's earnings per share (EPS) was -$1.61.
The next OTLK earnings call is Invalid Date. Add OTLK to your watchlist to be reminded of Outlook Therapeutics's next earnings date.
What was OTLK's earnings growth in the past year?
As of Outlook Therapeutics's earnings date in Invalid Date, Outlook Therapeutics's earnings has grown year over year. OTLK earnings in the past year totalled -$94.05 million.
Is Outlook Therapeutics profitable or losing money?
As of the last Outlook Therapeutics earnings report, Outlook Therapeutics is currently losing money. Outlook Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$94.05 million, a 55.87% increase year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.